HEALTHSTAT NEWS
STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.
Mentioned
Related Signal
Adjacent reporting
- Gilead and Merck’s latest trial success and flop
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
- STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
- An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
- Chinese drug reduces lung cancer death risk by 34% in trial